Abstract
The hairy/enhancer-of-split related with YRPW motif 1 (HEY1) is a member of the basic-helix-loop-helix-Orange (bHLH-O) family of transcriptional repressors that mediate Notch signaling. Several cancer-related pathways also regulate HEY1 expression, and HEY1 itself acts as an indirect positive regulator of the p53 tumor suppressor protein and a negative regulator of androgen receptor activity. In this study we show how a naturally occurring non-synonymous polymorphism at codon 94 of HEY1, which results in a substitution of leucine by methionine (Leu94Met), converts HEY1 from an androgen receptor corepressor to an androgen receptor co-activator without affecting its intrinsic transcriptional repressive domains. The polymorphism Leu94Met also abolishes HEY1-mediated activation of p53 and suppresses the ability of HEY1 to induce p53-dependent cell-cycle arrest and aberrant cell differentiation in human osteosarcoma U2OS cells. Moreover, expression of HEY1, but not of the variant Leu94Met, confers sensitivity to p53-activating chemotherapeutic drugs on U2OS cells. In addition, we have identified motifs in HEY1 that are critical for the regulation of its subcellular localization and analysed how mutations in those motifs affect both HEY1 and HEY1-Leu94Met functions. These findings suggest that the polymorphism Leu94Met in HEY1 radically alters its biological activities and may affect oncogenic processes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ban J, Bennani-Baiti IM, Kauer M, Schaefer KL, Poremba C, Jug G et al. (2008). EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Res 68: 7100–7109.
Belandia B, Powell SM, Garcia-Pedrero JM, Walker MM, Bevan CL, Parker MG . (2005). Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol Cell Biol 25: 1425–1436.
Contente A, Dittmer A, Koch MC, Roth J, Dobbelstein M . (2002). A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat Genet 30: 315–320.
Davis RL, Turner DL . (2001). Vertebrate hairy and enhancer of split related proteins: transcriptional repressors regulating cellular differentiation and embryonic patterning. Oncogene 20: 8342–8357.
Espinosa JM . (2008). Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene 27: 4013–4023.
Ferre-D’Amare AR, Prendergast GC, Ziff EB, Burley SK . (1993). Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain. Nature 363: 38–45.
Fuke S, Sasagawa N, Ishiura S . (2005). Identification and characterization of the Hesr1/Hey1 as a candidate trans-acting factor on gene expression through the 3′ non-coding polymorphic region of the human dopamine transporter (DAT1) gene. J Biochem 137: 205–216.
Gartel AL, Radhakrishnan SK . (2005). Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65: 3980–3985.
Giovannini C, Gramantieri L, Chieco P, Minguzzi M, Lago F, Pianetti S et al. (2009). Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. J Hepatol 50: 969–979.
Huang Q, Raya A, DeJesus P, Chao SH, Quon KC, Caldwell JS et al. (2004). Identification of p53 regulators by genome-wide functional analysis. Proc Natl Acad Sci USA 101: 3456–3461.
Hulleman E, Quarto M, Vernell R, Masserdotti G, Colli E, Kros JM et al. (2009). A role for the transcription factor HEY1 in glioblastoma. J Cell Mol Med 13: 136–146.
Hunter KW, Crawford NP . (2006). Germ line polymorphism in metastatic progression. Cancer Res 66: 1251–1254.
Iso T, Kedes L, Hamamori Y . (2003). HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 194: 237–255.
Iso T, Sartorelli V, Chung G, Shichinohe T, Kedes L, Hamamori Y . (2001a). HERP, a new primary target of Notch regulated by ligand binding. Mol Cell Biol 21: 6071–6079.
Iso T, Sartorelli V, Poizat C, Iezzi S, Wu HY, Chung G et al. (2001b). HERP, a novel heterodimer partner of HES/E(spl) in Notch signaling. Mol Cell Biol 21: 6080–6089.
Itoh F, Itoh S, Goumans MJ, Valdimarsdottir G, Iso T, Dotto GP et al. (2004). Synergy and antagonism between Notch and BMP receptor signaling pathways in endothelial cells. EMBO J 23: 541–551.
Karsenty G . (2008). Transcriptional control of skeletogenesis. Annu Rev Genomics Hum Genet 9: 183–196.
Knudson AG . (2001). Two genetic hits (more or less) to cancer. Nat Rev Cancer 1: 157–162.
Lengner CJ, Steinman HA, Gagnon J, Smith TW, Henderson JE, Kream BE et al. (2006). Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol 172: 909–921.
Leong KG, Gao WQ . (2008). The Notch pathway in prostate development and cancer. Differentiation 76: 699–716.
Lu C, El-Deiry WS . (2009). Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis 14: 597–606.
Maier MM, Gessler M . (2000). Comparative analysis of the human and mouse Hey1 promoter: Hey genes are new Notch target genes. Biochem Biophys Res Commun 275: 652–660.
Nakagawa O, McFadden DG, Nakagawa M, Yanagisawa H, Hu T, Srivastava D et al. (2000). Members of the HRT family of basic helix-loop-helix proteins act as transcriptional repressors downstream of Notch signaling. Proc Natl Acad Sci USA 97: 13655–13660.
Pietsch EC, Humbey O, Murphy ME . (2006). Polymorphisms in the p53 pathway. Oncogene 25: 1602–1611.
Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G et al. (2001). A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409: 928–933.
Sakamoto M, Hirata H, Ohtsuka T, Bessho Y, Kageyama R . (2003). The basic helix-loop-helix genes Hesr1/Hey1 and Hesr2/Hey2 regulate maintenance of neural precursor cells in the brain. J Biol Chem 278: 44808–44815.
Satow T, Bae SK, Inoue T, Inoue C, Miyoshi G, Tomita K et al. (2001). The basic helix-loop-helix gene hesr2 promotes gliogenesis in mouse retina. J Neurosci 21: 1265–1273.
Sivertsen EA, Huse K, Hystad ME, Kersten C, Smeland EB, Myklebust JH . (2007). Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells. Eur J Immunol 37: 2937–2948.
Tanaka M, Setoguchi T, Hirotsu M, Gao H, Sasaki H, Matsunoshita Y et al. (2009). Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer 100: 1957–1965.
Undevia SD, Gomez-Abuin G, Ratain MJ . (2005). Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 5: 447–458.
Villaronga MA, Bevan CL, Belandia B . (2008). Notch signaling: a potential therapeutic target in prostate cancer. Curr Cancer Drug Targets 8: 566–580.
Whibley C, Pharoah PD, Hollstein M . (2009). p53 polymorphisms: cancer implications. Nat Rev Cancer 9: 95–107.
Yang J, Weinberg RA . (2008). Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14: 818–829.
Zamurovic N, Cappellen D, Rohner D, Susa M . (2004). Coordinated activation of notch, Wnt, and transforming growth factor-beta signaling pathways in bone morphogenic protein 2-induced osteogenesis. Notch target gene Hey1 inhibits mineralization and Runx2 transcriptional activity. J Biol Chem 279: 37704–37715.
Zavadil J, Cermak L, Soto-Nieves N, Bottinger EP . (2004). Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J 23: 1155–1165.
Zhang Y, Wang Z, Ahmed F, Banerjee S, Li Y, Sarkar FH . (2006). Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int J Cancer 119: 2071–2077.
Acknowledgements
We thank Ana Aranda for her continuous support and Linn Markert for technical assistance. This study was supported by the MICINN (SAF2007-62642, SAF2006-07785), the Fundación de Investigación Médica Mutua Madrileña, the FIS (RD06/0020/0036), the CRESCENDO (FP-018652) and Cancer Research UK (C11509/A8570).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Supplementary information
Rights and permissions
About this article
Cite this article
Villaronga, M., Lavery, D., Bevan, C. et al. HEY1 Leu94Met gene polymorphism dramatically modifies its biological functions. Oncogene 29, 411–420 (2010). https://doi.org/10.1038/onc.2009.309
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.309
Keywords
This article is cited by
-
Crosstalk between MEIS1 and markers of different cell signaling pathways in esophageal squamous cell carcinoma
Molecular Biology Reports (2020)
-
CHK1 expression in Gastric Cancer is modulated by p53 and RB1/E2F1: implications in chemo/radiotherapy response
Scientific Reports (2016)
-
Hairy/enhancer-of-split related with YRPW motif protein 1 promotes osteosarcoma metastasis via matrix metallopeptidase 9 expression
British Journal of Cancer (2015)
-
Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients
British Journal of Cancer (2013)
-
Specific changes in the expression of imprinted genes in prostate cancer—implications for cancer progression and epigenetic regulation
Asian Journal of Andrology (2012)